Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Reduced MRI-based Right-to-Left Ventricular Blood Pool T2 Ratio Predicts Adverse Events and Impaired Cardiopulmonary Function in Heart Failure Patients
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 18 - IMAGEM AVANÇADA E BIOMARCADORES NA ESTRATIFICAÇÃO DE RISCO CARDIOVASCULAR: DA RESSONÂNCIA MAGNÉTICA DE PERFUSÃO À REMODELAGEM CARDÍACA
Speaker:
Ana Débora Câmara De Sá
Congress:
CPC 2025
Topic:
B. Imaging
Theme:
03. Imaging
Subtheme:
03.3 Cardiac Magnetic Resonance
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Débora Sá; Ana Rita Bello; Pedro Lopes; Gonçalo Cunha; Bruno Rocha; Pedro Freitas; Sara Guerreiro; Cláudia Silva; Kamil Stankowski; Francisco Gama; João Abecassis; António Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Background:</strong> Cardiovascular magnetic resonance (CMR) T2 mapping is a sensitive tool for assessing blood oxygenation levels. A reduced right ventricular (RV) to left ventricular (LV) blood pool (BP) T2 relaxation time has been observed in patients with Heart Failure (HF) - due to increased peripheral oxygen extraction -, but its association with adverse clinical outcomes and physiologic parameters remains unexplored. This study aimed to assess the prognostic value of the RV/LV BP T2 ratio and its correlation with cardiopulmonary exercise metrics in patients with HF with reduced and mildly reduced ejection fraction (HFrEF and HFmrEF).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> This retrospective, single-center cohort study included adult patients with HF and LVEF <50% who underwent CMR with T2 mapping (T2-prep SSFP) between 2019-2024. Patients with congenital heart disease and/or known shunts were excluded. RV and LV BP T2 values were measured on a mid-ventricular short-axis slice, excluding trabeculations, papillary muscles, and inflow artifacts. The study endpoint was a composite of all-cause death or hospital admission for decompensated HF. In a subset of patients who underwent clinically indicated cardiopulmonary exercise testing (CPET) within one year of CMR, RV/LV BP T2 ratio was correlated with metrics of HF severity. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results:</strong> A total of 301 patients were included (66% male, mean age 60±16 years, median LVEF 35%; 36% with ischemic etiology). The mean RV/LV BP T2 ratio was 0.70±0.11. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">After a median follow-up of 22±17months, 49 patients (14.1%) experienced the outcome (31 deaths, 18 HF hospitalizations). ROC curve analysis showed good discriminatory power of RV/LV BP T2 ratio for predicting outcome, with an AUC of 0.76 (95% CI: 0.69-0.83, p = 0.001). A RV/LV BP T2 ratio cut-point of 0.72 had 94% sensitivity and 46% specificity for MACE. Patients with values ≤ 0.72 represent 61% of the population but account for 94% of the events – Figure 2. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">After Cox regression adjustment for age, LVEF, NYHA class and ischemic etiology, RV/LV BP T2 ratio remained an independent predictor of outcome (adjusted HR 0.92 per 1% increase, 95%CI 0.89-0.96, p<0.001). </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">In the subset of 49 patients with CPET, RV/LV BP T2 ratio correlated with peak oxygen uptake (VO2, r= 0.43, p=0.002) and ventilatory efficiency (VE/VCO2, r=-0.34, p=0.020).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Conclusion:</strong> Decreased RV/LV T2 ratio correlates with impaired CPET parameters and is independently associated with higher risk of death and HF hospitalization. This biomarker can be readily obtained from routine CMR protocols and may serve as an additional tool to aid in assessing HF severity and prognosis. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site